VR Adviser
Latest statistics and disclosures from VR Adviser's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APGE, FDMT, OCUL, SYRE, MRUS, and represent 46.79% of VR Adviser's stock portfolio.
- Added to shares of these 10 stocks: OCUL (+$45M), ENGN (+$44M), DNTH (+$35M), EWTX (+$33M), FDMT (+$31M), ORIC (+$27M), KALV (+$26M), AQST (+$24M), Adverum Biotechnologies (+$22M), PRAX (+$22M).
- Started 9 new stock positions in Adverum Biotechnologies, IMTX, EWTX, IPSC, ENGN, TNYA, Cg Oncology, MLYS, AQST.
- Reduced shares in these 10 stocks: Rayzebio (-$251M), Ambrx Biopharma (-$30M), RYTM (-$23M), CELC (-$20M), CABA (-$17M), SVRA (-$17M), MRUS (-$16M), GHRS (-$7.6M), SYRE (-$7.6M), TERN (-$7.1M).
- Sold out of its positions in Adverum Biotechnologies, MIST, Ambrx Biopharma, Rayzebio, RYTM, SVRA, GHRS.
- VR Adviser was a net buyer of stock by $19M.
- VR Adviser has $2.1B in assets under management (AUM), dropping by 44.18%.
- Central Index Key (CIK): 0001615982
Tip: Access up to 7 years of quarterly data
Positions held by VR Adviser consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for VR Adviser
VR Adviser holds 38 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apogee Therapeutics (APGE) | 26.8 | $564M | 8.5M | 66.45 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 6.7 | $140M | +28% | 4.4M | 31.86 |
|
| Ocular Therapeutix (OCUL) | 5.5 | $116M | +64% | 13M | 9.10 |
|
| Spyre Therapeutics Com New (SYRE) | 3.9 | $82M | -8% | 2.2M | 37.93 |
|
| Merus N V (MRUS) | 3.8 | $81M | -16% | 1.8M | 45.03 |
|
| Pharvaris N V (PHVS) | 3.7 | $79M | 3.4M | 23.11 |
|
|
| Kalvista Pharmaceuticals (KALV) | 3.5 | $74M | +52% | 6.2M | 11.86 |
|
| Enliven Therapeutics (ELVN) | 3.4 | $71M | +36% | 4.0M | 17.59 |
|
| Miragen Therapeutics (VRDN) | 3.2 | $68M | 3.9M | 17.51 |
|
|
| Dianthus Therapeutics (DNTH) | 3.0 | $63M | +125% | 2.1M | 30.00 |
|
| Dyne Therapeutics (DYN) | 2.9 | $62M | 2.2M | 28.39 |
|
|
| Applied Therapeutics (APLT) | 2.9 | $62M | +45% | 9.1M | 6.80 |
|
| Oric Pharmaceuticals (ORIC) | 2.9 | $60M | +80% | 4.4M | 13.75 |
|
| Astria Therapeutics (ATXS) | 2.4 | $51M | +11% | 3.6M | 14.07 |
|
| Mersana Therapeutics (MRSN) | 2.4 | $51M | 11M | 4.48 |
|
|
| Engene Holdings (ENGN) | 2.1 | $44M | NEW | 2.6M | 16.95 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.0 | $43M | +99% | 706k | 61.02 |
|
| Hillevax (HLVX) | 1.6 | $35M | 2.1M | 16.63 |
|
|
| Cogent Biosciences (COGT) | 1.6 | $35M | +9% | 5.1M | 6.72 |
|
| Edgewise Therapeutics (EWTX) | 1.6 | $33M | NEW | 1.8M | 18.24 |
|
| Cabaletta Bio (CABA) | 1.3 | $27M | -39% | 1.6M | 17.06 |
|
| Arvinas Ord (ARVN) | 1.2 | $26M | 628k | 41.28 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 1.2 | $26M | -13% | 9.0M | 2.87 |
|
| Aquestive Therapeutics (AQST) | 1.1 | $24M | NEW | 5.6M | 4.26 |
|
| Terns Pharmaceuticals (TERN) | 1.1 | $22M | -24% | 3.4M | 6.56 |
|
| Adverum Biotechnologies Com New | 1.0 | $22M | NEW | 1.6M | 14.14 |
|
| Celcuity (CELC) | 1.0 | $21M | -48% | 970k | 21.60 |
|
| Abivax Sa Sponsored Ads (ABVX) | 0.9 | $19M | +34% | 1.3M | 14.30 |
|
| Immatics SHS (IMTX) | 0.9 | $18M | NEW | 1.8M | 10.51 |
|
| Lyra Therapeutics (LYRA) | 0.8 | $16M | 2.6M | 6.22 |
|
|
| Cg Oncology | 0.7 | $15M | NEW | 350k | 43.90 |
|
| Century Therapeutics (IPSC) | 0.7 | $14M | NEW | 3.4M | 4.18 |
|
| Trevi Therapeutics (TRVI) | 0.6 | $12M | 3.4M | 3.45 |
|
|
| Tenaya Therapeutics (TNYA) | 0.4 | $8.1M | NEW | 1.6M | 5.23 |
|
| Mineralys Therapeutics (MLYS) | 0.3 | $7.2M | NEW | 556k | 12.91 |
|
| Acelyrin (SLRN) | 0.3 | $6.3M | 937k | 6.75 |
|
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.2 | $5.2M | 250k | 20.67 |
|
|
| Olema Pharmaceuticals (OLMA) | 0.0 | $872k | 77k | 11.32 |
|
Past Filings by VR Adviser
SEC 13F filings are viewable for VR Adviser going back to 2020
- VR Adviser 2024 Q1 filed May 15, 2024
- VR Adviser 2023 Q4 filed Feb. 14, 2024
- VR Adviser 2023 Q3 filed Nov. 14, 2023
- VR Adviser 2023 Q2 filed Aug. 11, 2023
- VR Adviser 2022 Q2 restated filed May 15, 2023
- VR Adviser 2022 Q3 restated filed May 15, 2023
- VR Adviser 2022 Q4 restated filed May 15, 2023
- VR Adviser 2023 Q1 filed May 15, 2023
- VR Adviser 2022 Q4 filed Feb. 14, 2023
- VR Adviser 2022 Q3 filed Nov. 14, 2022
- VR Adviser 2022 Q2 filed Aug. 15, 2022
- VR Adviser 2022 Q1 filed May 16, 2022
- VR Adviser 2021 Q4 filed Feb. 14, 2022
- VR Adviser 2021 Q3 filed Nov. 15, 2021
- VR Adviser 2021 Q2 filed Aug. 13, 2021
- VR Adviser 2021 Q1 filed May 14, 2021